What is the acquisition price offered by Eli Lilly for ATAI?

The acquisition price is $13.00 per share, with a total deal value of approximately $1.5 billion.

How did the acquisition news affect ATAI stock?

The stock closed at $12.50, slightly below the deal price, indicating the market sees some risk in deal completion.

ATAI Stock Downgraded After Eli Lilly Buyout Agreement

H.C. Wainwright and Berenberg downgraded ATAI Life Sciences stock after Eli Lilly announced an acquisition agreement, believing the deal price caps near-term upside potential.

July 20, 2026

2 min read

Source: Stocktwits

H.C. Wainwright and Berenberg have downgraded ATAI Life Sciences (ATAI) stock following Eli Lilly's (LLY) acquisition agreement, according to reports from financial platform Stocktwits.

Rating Changes

H.C. Wainwright: Downgraded from 'Buy' to 'Neutral'.
Berenberg: Downgraded from 'Buy' to 'Hold'.

Analyst Rationale

Analysts believe the acquisition price offered by Eli Lilly limits the near-term upside potential for ATAI shares, as the deal may cap the stock price. Uncertainty regarding the completion of the deal and regulatory approvals also adds risk.

Context

The downgrades come after ATAI agreed to be acquired by Eli Lilly in a deal valued at approximately $1.5 billion. ATAI closed trading on Friday at $12.50, slightly below the deal price of $13.00 per share.

Conclusion

The downgrades suggest investors may not see significant gains in ATAI stock in the near term, as the acquisition price caps upside. However, the deal still provides a premium to current shareholders.

Frequently Asked Questions

Because the acquisition price from Eli Lilly limits the stock's near-term upside potential, reducing its attractiveness to investors.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.